Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma

Area of Science:

• Oncology
• Gastroenterology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is associated with high patient mortality.
• Multimodal therapy, encompassing surgical resection and systemic chemotherapy, is a cornerstone in PDAC management.

Purpose of the Study:

• To review current neoadjuvant treatment strategies for resectable and borderline resectable PDAC.
• To highlight the importance of ongoing and recent clinical trials in refining PDAC treatment.
• To identify future research directions for improving outcomes in PDAC.

Main Methods:

• Review of established multimodal therapy protocols for PDAC.
• Analysis of data from ongoing and recently completed clinical trials in PDAC management.
• Synthesis of current understanding of PDAC tumor biology and treatment responses.

Main Results:

• Neoadjuvant treatment strategies are integral to the management of resectable and borderline resectable PDAC.
• Results from recent trials are providing critical insights into optimizing PDAC treatment paradigms.
• Further research is needed to understand tumor biology and identify novel therapeutic targets.

Conclusions:

• Advances in understanding tumor biology and developing novel agents are essential for improving PDAC outcomes.
• Combination treatment strategies hold promise for enhancing the efficacy of PDAC therapy.
• Future studies should focus on integrating biological insights with innovative treatment approaches for PDAC.